Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience
1996

Improving Treatment for Testicular Cancer

Sample size: 266 publication Evidence: moderate

Author Information

Author(s): A Gerl, C Clemm, N Schmeller, R Hartenstein, R Lamerz, W Wilmanns

Primary Institution: Klinikum Grosshadern of the University of Munich

Hypothesis

Does the use of etoposide in chemotherapy improve survival rates for patients with metastatic non-seminomatous germ cell tumors?

Conclusion

The study found that etoposide-containing chemotherapy significantly improved survival rates in patients with poor-risk metastatic non-seminomatous germ cell tumors.

Supporting Evidence

  • The overall 3-year survival rate was 77%.
  • Patients without poor-risk factors had a 3-year survival of 91%.
  • Etoposide-containing protocols led to significantly improved survival in patients with poor-risk factors.

Takeaway

This study looked at how well patients with a type of testicular cancer did after treatment. It found that using a specific medicine called etoposide helped many patients live longer.

Methodology

The study reviewed long-term outcomes of 266 patients treated with cisplatin-based chemotherapy and analyzed prognostic factors affecting survival.

Potential Biases

Potential biases may arise from the observational nature of the study and the lack of randomization in treatment protocols.

Limitations

The study was conducted at a single institution, which may limit the generalizability of the results.

Participant Demographics

Median age at diagnosis was 27 years, with a range from 16 to 72 years.

Statistical Information

P-Value

0.046

Confidence Interval

95% CI 72 - 82%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication